- Home
- LNN vs KNSA Comparison
LNN vs KNSA Comparison
Compare LNN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNN | KNSA |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United Kingdom |
| Employees | 1275 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 2.6B |
| IPO Year | 1988 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LNN | KNSA |
|---|---|---|
| Price | $121.07 | $43.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $136.00 | $51.33 |
| AVG Volume (30 Days) | 143.1K | ★ 376.8K |
| Earning Date | 01-06-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 6.78 | 0.47 |
| Revenue | ★ $676,368,000.00 | $597,973,000.00 |
| Revenue This Year | N/A | $62.63 |
| Revenue Next Year | $7.54 | $29.93 |
| P/E Ratio | ★ $17.91 | $89.97 |
| Revenue Growth | 11.41 | ★ 55.68 |
| 52 Week Low | $106.10 | $17.82 |
| 52 Week High | $150.96 | $42.98 |
Technical Indicators
Market Signals| Indicator | LNN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 63.61 |
| Support Level | $115.40 | $40.77 |
| Resistance Level | $123.79 | $42.32 |
| Average True Range (ATR) | 3.10 | 1.43 |
| MACD | 0.51 | 0.01 |
| Stochastic Oscillator | 49.61 | 76.69 |
Price Performance
Historical ComparisonAbout LNN Lindsay Corporation
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.